Spoilers: The hazards, if present, always need to be addressed.
I prefer to see a risk control options analysis (at the Hazard Analysis level) that (for each line) identifies:
For (2) It is typical that numeric ratings in risk management files are qualitative and make no effort to be quantitative (see numerous posts by @Bev D )... but often in the case of quantitative assessments it is impossible to collect enough data to demonstrate the magnitude of improvement that would be reflected in an improvement in ratings. For example: it may be completely justifiable that something happens at a ratio no worse than 1-in-1000.... but to construct a study to demonstrate with confidence that the "improved" rate is no worse than 1-in-10000 (a change of "an order of magnitude"), this is typically not the sort of effort that medical device manufacturers invest in as part of improving a single line of analysis in a RMF. I recommend simply saying something like "based on ____, we believe that the acceptability profile improved, but we cannot justify changing the rating value after implementing the controls."
For (3), this is where you blow off implementing controls for the risk and explain why.
I prefer to see a risk control options analysis (at the Hazard Analysis level) that (for each line) identifies:
- Which implemented risk controls are responsible for the documented improvement in the acceptability, or
- Why, despite the implementation of document risk controls, there is no improvement in the acceptability rating of a line, or
- Why no risk controls were implemented for this line of analysis.
For (2) It is typical that numeric ratings in risk management files are qualitative and make no effort to be quantitative (see numerous posts by @Bev D )... but often in the case of quantitative assessments it is impossible to collect enough data to demonstrate the magnitude of improvement that would be reflected in an improvement in ratings. For example: it may be completely justifiable that something happens at a ratio no worse than 1-in-1000.... but to construct a study to demonstrate with confidence that the "improved" rate is no worse than 1-in-10000 (a change of "an order of magnitude"), this is typically not the sort of effort that medical device manufacturers invest in as part of improving a single line of analysis in a RMF. I recommend simply saying something like "based on ____, we believe that the acceptability profile improved, but we cannot justify changing the rating value after implementing the controls."
For (3), this is where you blow off implementing controls for the risk and explain why.